Claims for Patent: 10,662,243

Summary for Patent: 10,662,243

Title:	Dosage regimen for administering a CD19XCD3 bispecific antibody
Abstract:	The disclosure provides a method for assessing the risk of potential adverse effects for a human patient mediated by the administration of a CD19×CD3 bispecific antibody to said patient comprising determining the ratio of B cells to T cells of said patient. The disclosure also provides a method for administering a CD19×CD3 bispecific antibody to a human patient having a B:T cell ratio of about 1:5 or lower, comprising administering doses in a dosing regimen. This dosing regimen can be applied in methods for treating malignant CD19 positive lymphocytes or for ameliorating and/or preventing an adverse effect mediated by the administration of said bispecific antibody. The Also provided is a pharmaceutical package or kit comprising a first dose and a second dose and optionally a third dose of said antibody.
Inventor(s):	Dirk Nagorsen, Peter Kufer, Gerhard Zugmaier, Patrick Bauerle
Assignee:	Amgen Research Munich GmbH
Application Number:	US14/491,459

Details for Patent 10,662,243

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	ACTEMRA	tocilizumab	Injection	125276	January 08, 2010		2034-09-19

International Patent Family for US Patent 10,662,243

Country	Patent Number	Estimated Expiration
South Africa	201201774
World Intellectual Property Organization (WIPO)	2011051307
United States of America	8840888